Aclaris Therapeutics Announces Appointment of Bryan Reasons as a Director and Chairman of the Audit Committee
April 24 2018 - 4:05PM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led
biopharmaceutical company committed to identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in aesthetic and medical dermatology and immunology, today
announced the appointment of Bryan Reasons as a director and
Chairman of the Audit Committee.
Bryan Reasons has served as the Senior Vice President, Finance
and Chief Financial Officer of Impax Laboratories Inc. since 2012.
Prior to joining Impax, Mr. Reasons was with Cephalon, Inc., a
biopharmaceutical company, serving as Vice President, Finance from
2010 to 2011 and as Vice President, Risk Management and General
Auditor from 2005 to 2010. Following the acquisition of Cephalon by
Teva Pharmaceutical Industries Ltd., he served as Vice President,
Finance of Teva from November 2011 to January 2012. Prior to
joining Cephalon, Mr. Reasons held various financial management
positions at DuPont and previously worked at PricewaterhouseCoopers
LLP, including as a senior manager. Mr. Reasons has a B.S. degree
in accounting from The Pennsylvania State University and an M.B.A.
degree from Widener University. He is a certified public
accountant in the Commonwealth of Pennsylvania.
“I'd like to take this opportunity to welcome our new board
member, Bryan Reasons, who will serve as an independent director
and Audit Committee Chair. His significant experience in the
healthcare industry will be an invaluable asset for Aclaris as we
evolve into a fully integrated biopharmaceutical company," said
Neal Walker, President and Chief Executive Officer.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company committed to identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in dermatology, both aesthetic and medical, and immunology.
Aclaris’ focus on market segments with no FDA-approved medications
or where treatment gaps exist has resulted in the first
FDA-approved treatment for raised seborrheic keratoses and several
clinical programs to develop medications for the potential
treatment of common warts, alopecia areata, and vitiligo. For
additional information, please visit www.aclaristx.com and follow
Aclaris on LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
"believe", "expect", "may", "plan," "potential," "will," and
similar expressions, and are based on Aclaris' current beliefs and
expectations. These forward-looking statements include expectations
regarding Aclaris’ potential evolution into a fully integrated
biopharmaceutical company. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those reflected in such statements. Risks and uncertainties
that may cause actual results to differ materially include
uncertainties inherent in the conduct of clinical trials, Aclaris'
reliance on third parties over which it may not always have full
control, and other risks and uncertainties that are described in
the Risk Factors section of Aclaris' Annual Report on Form 10-K
filed for the year ended December 31, 2017 and other filings
Aclaris makes with the U.S. Securities and Exchange Commission from
time to time. These documents are available under the "Financial
Information" section of the Investors page of Aclaris' website at
http://www.aclaristx.com. Any forward-looking statements speak only
as of the date of this press release and are based on information
available to Aclaris as of the date of this release, and Aclaris
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Aclaris ContactMichael Tung, M.D.Senior Vice
PresidentCorporate Strategy/Investor
Relations484-329-2140mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024